chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At approximately 6:00 pm the same day I received the vaccine, I experienced chills that continued until falling asleep at around 9:30 pm. At midnight I woke up extremely hot, as if I had a fever (I didn't confirm this with a thermometer, I was just extremely hot and sweaty) and I had a very severe, painful headache that lasted at least 30 minutes until I took two acetaminophen pills. I also experienced the usual muscle pains. All symptoms were gone by Saturday morning upon waking.
Tetanus given and within 5 minutes, patient became ashen, became dizzy, BP 60/42, P60, thready and weak. Benadryl 50mg IM given after five minutes patient BP 96/62, complained of feeling itchy, hot and tremulous, 15 minutes after injection became cold and shaky: covered with blanket. 30 min after Benadryl no shaking, feeling better,no dizziness.
This is a spontaneous report from a contactable consumer who reported for his elderly father. An 87-year-old male patient received a single dose of PREVNAR 13 (Lot Number, and Expiration date not available), via an unspecified route of administration on 23Feb2015. Medical history included chronic obstructive pulmonary disease (COPD) at least ten years, congestive heart failure about two years, and mitral valve prolapse about two to three years ago. Concomitant medications included BUMEX, SPIRIVA, digoxin for congestive heart failure, metolazone 2.5 mg tablet once a day by mouth for congestive heart failure, CENTRUM 50 and over tablet once a day by mouth for supplement, fish oil capsule once a day by mouth for supplement. On 23Feb2015, the patient experienced chills with outcome of not recovered. Follow-up (13Mar2015): New information reported from another contactable consumer includes: reporter information. Follow-up attempts are completed. No further information is expected.
07/28/2022 Very bad sinus congestion runny nose and I had a slight fever. Talked to a dr and was given augmented and prozone because because we thought it was a sinus infection because I took a COVID-19 Test and it was negative. Sunday, It got worse so I took another test which was positive and I was given Paxlovid from my Primary doctor. I took one dose and had an allergic reaction, so I stopped taking it. I was then told to go back on the previous medication, and I had no sore throat. After about 5 days I saw improvement, but I was still positive 10 days later. Throughout this entire ordeal I took Tylenol and Motrin for the fever and pain. It started to resolve itself, but I was positive for about 30 days and I was extremely tired during this time.  9/10/22  I had to be treated with the same medication again because I had sinus issues and it didn?t completely resolve until mid September.
The Covid vaccine EXP date as per the labels on the immunization box is 01/31/2024, but the BUD Expiration date from the Pharmacy is 06/07/2023.  The vaccine was given pass the BUD Expiration date.
Patient noted a silver dollar sized red, hot and rasied itchy area on the morning of 4/23/15. Patient took 1 BENADRYL at 10:45 am on 4/23/15.
Itching; redness; rash; hives; tightness in throat, felt like there was something in my throat; This is a spontaneous report from a contactable consumer (patient). A 38-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: Er8729), via an unspecified route of administration, administered in Arm Left on 11Apr2021 07:30 (age at the time of vaccination 38-years-old), as a single dose for COVID-19 immunization. The patient's medical history included asthma. The patient's concomitant medications included Ibuprofen, and inhaler. Patient had no Known allergies. On 11Apr2021 08:30, the patient Itching, redness, rash, hives, and tightness in throat, felt like there was something in my throat. Adverse events result in Emergency room/department or urgent care. Treatment received for the adverse event which included prescribe prednisone, cetirizine, and Benadryl. No other vaccine in four weeks. No covid prior vaccination. No covid tested post vaccination. The outcome for all the events was recovering.  No follow-up attempts are Possible. No further information is expected.
Extreme muscle ache in hip joints, legs, neck, back of head, shoulders and small of back. Lack of energy. Severe Headache that one day sent me to the ER. Another day trouble breathing  that sent me back to the ER for second time.  Pain so bad during first three weeks that I couldn't sleep at night, or walk correctly during the day.
Received the 1st of 2 shots  of covid -19 vaccine on 7/28 at the pharmacy.  Injection site was  my left shoulder.  After 2 days, began to feel chest tightness, heart feels like there is inflammation.  Also shortness of breath and light headed mess.  Went to immediate care and was prescribed albuterol inhaler and  Azithromyacin 5 day antibiotic treatment.   Tightness and inflammation still present after completing dr prescribed treatment.
About 1 1/2 hour after injection, one hive appeared on face.  Face and arm, head itchy.  No rash.
I got the sore arm the evening of the vaccine, and on 11/09/2022, I had a headache about a day and a half after the vaccine. Pain scale would have been a 5 for my headache. And then for the sinus infection, on 11/08/2022, I got a sore tooth on the left upper molar from the pressure of the sinus right above it. And a lot of colored mucous, stuffy head, headaches, just not feeling well, just staying in bed and the chair kind of day, and it lasted about 3 weeks. I did get medication after 10 days. It was definitely a bacterial infection. I had that sinus headache. I got a couple of sores in my nose. They gave me amoxicillin and mupirocin an antibiotic ointment to use in my nose for my sores. The doctor told me after 10 days, they assume it is a bacterial infection. Within 24 hours of taking the amoxicillin I felt a whole lot better.
This spontaneous report was received from a medical assistant and refers to unspecified patients of unknown age and gender. No information about the patients' medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided.     On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB injection, lot# M032649, expiration date: 11-NOV-2018 (dose and route of administration were not reported). The vaccine was exposed to temperature from 32 to 36 degrees Fahrenheit (also reported as 35 degrees Fahrenheit ) for 12 hours. Digital data logger was not involved and there was no previous temperature excursion. No adverse effect was reported. Product quality compliant was not involved. This one of several reports received from the same reporter.  Additional information has been requested.; Sender's Comments: US-009507513-1701USA007887: US-009507513-1701USA005252: US-009507513-1701USA007886:
MD reported that pt devel a t103 2hr post vax @ well baby clinic;pt also devel sz p/elevated temp;
Chills; Vomiting; Diarrhea; This case was reported by a consumer via other manufacturer and described the occurrence of chills in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced chills, vomiting and diarrhea. On an unknown date, the outcome of the chills, vomiting and diarrhea were unknown.   It was unknown if the reporter considered the chills, vomiting and diarrhea to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination not reported. The reporter stated, she experienced chills, vomiting and diarrhea, after unspecified shingles vaccine. The reporter did not want to fill adverse event report form. The case had been linked with US2021AMR072113 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR072113:same reporter
Light headed, tunnel vision, achy, lethargy. Temp 101.2 x 2 days. Red rash at injection site (3 days after).
check-up unremarkable-recv vax & t103-104,irritable,fussy,vomit,inconsolable would not eat;dx w/vax rxn;lost 5 ounces;DT in future
59 year old male asthmatic patient came in to pharmacy with prescription from his physician to receive Arexvy; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intercepted drug prescribing error in a 59-year-old male patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   Concurrent medical conditions included asthma.   On an unknown date, the patient did not received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced intercepted drug prescribing error (Verbatim: 59 year old male asthmatic patient came in to pharmacy with prescription from his physician to receive Arexvy). The outcome of the intercepted drug prescribing error was unknown.   Additional Information: GSK receipt date 17 Oct 2023 The pharmacist stated a 59 year old male asthmatic patient came in to pharmacy with prescription from his physician to receive Arexvy. The vaccine had not been administered which led to intercepted drug prescribing error.  The Vaccine Administration Facility was the same as primary reporter.
Case number PHEH2014US025066, is an initial spontaneous report received from a nurse on 09 Dec 2014. This report refers to a 90 year old female patient. Medical history and concomitant medication were not reported. She was vaccinated with FLUVIRIN (batch number: 145701) intramuscularly at a dose of 0.5 ml on 23 Oct 2014. Nurse reported that patient received FLUVIRIN that was 49 degree F 12 times over a period of 34 days. The temperature excursions began around 16 Oct 14. 12 separate temperature excursions lasting 30 minutes each in which the temperature was 46-49 degree F during each of those excursions. No adverse event was reported following this maladministration. No further information was provided.
Initial report was received on 04 October 2013 from a consumer who is also the patient. A female patient (date of birth not reported) had received "several years ago" an Influenza vaccine (manufacturer, lot number, route, site and date of administration not reported) and an unspecified amount of time later, experienced a fever of "107" and a seizure. According to the reporter, "doctors said it was adjuvant in the vaccine". No further information was available, at the time of the report. The patient's outcome was recovered. Documents held by sender: none.
Roughly 25-30 minutes following receiving the shot, I became extremely dizzy and weak.  A few minutes later I felt difficulty breathing and realized that my throat was swelling.  My heart began to race, but I cannot say if that was a result of the other symptoms I was experiencing.   The dizziness and weakness lasted for about 2 hours. The difficulty breathing and swollen throat eased after about 7 hours.  Just as I thought that I was feeling better, a fever set in around 11pm along with the chills, joint aches and pains, and general malaise. These flu-like symptoms lasted for roughly 36 hours.
Patient received  3 doses; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date) and Shingrix (received 2nd dose on an unknown date).   On an unknown date, the patient received the 3rd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The reporter stated that, an unknown patient received 3 doses of Shingrix vaccine, which led to extra dose administered. The reporter consented to follow up.
Small amount of puffiness under my left eye; A non-serve fine itchy rash appeared on my face and neck only; This is a spontaneous report from a contactable consumer, the patient. A 73-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 24Apr2021 (at the age of 73-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 24Apr2021, around 17:00, a non-serve fine itchy rash appeared on patients face and neck only; with small amount of puffiness under her left eye. The patients temperature had remained around 98.3 degree (units unspecified). Her intake included lots of water. On 25Apr2021, the rash was getting better, but there was some itching. On the day of report the rash and itch was almost gone. Overall, the patient had no other symptoms at anytime. Therapeutic measures were taken as a result of the itchy rash and included hydrocortisone (MANUFACTURER UNKNOWN) cream (reported as generic Hydrocortisone Cream (fast itch and rash relief)). The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event a non-serve fine itchy rash appeared on the face and neck only; with small amount of puffiness under her left eye was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from a practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 16-NOV-2017, the patient was vaccinated with an improperly stored dose of GARDASIL 9 (strength and route were unknown) (lot# N019923 and expiration date 28-APR-2019) for prophylaxis (Incorrect product storage). No adverse event was reported. The excursion temperature on 08-NOV-2017, 16-NOV-2017, 23-JAN-2018, 06-JUN-2018, 03-JUL-2018 and 14-AUG-2018 was 47 degree Celsius for maximize 15 hours. The excursion temperature on 07-DEC-2017 was 50 degree Celsius for maximize 8.75 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1810USA001951; US-009507513-1810USA001952; US-009507513-1810USA001953; US-009507513-1810USA001954; US-009507513-1810USA001955; US-009507513-1810USA001957; US-009507513-1810USA001958; US-009507513-1810USA001959; US-009507513-1809USA003709.
Congestion; Body aches; Fever; Headache; Chills; Loss of taste; Loss of smell; Coughing up phlegm; This is a spontaneous report from a non-contactable consumer, the patient. A 38-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 301308A) via an unspecified route of administration in the left arm on 27Sep2021 at 15:30 (at the age of 38-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 28Sep2021, the patient experienced congestion, body aches, fever, headache, chills, loss of taste, loss of smell and coughing up phlegm. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events congestion, body aches, fever, headache, chills, loss of taste, loss of smell and coughing up phlegm was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
extreme muscle tightness, particularly behind both knees/hamstrings, but in upper body as well--has continued through current time (3 months) itchy armpits--also has continued
Employee received flu vaccination on 10-31-12. On 11-2-12 she developed a rash with pruritus without respiratory symptoms. With the use of CLARITIN the symptoms resolved. Novartis FLUVIRIN Lot: 123203 Exp: 06/2013.
Heart palpitations; irregular breathing; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A 36-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunisation. The following information was reported: PALPITATIONS (non-serious), outcome "not recovered", described as "Heart palpitations"; IRREGULAR BREATHING (non-serious), outcome "not recovered". The events "heart palpitations" and "irregular breathing" required physician office visit and emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of palpitations, irregular breathing.  Additional information: Reportedly, the patient had many tests and wore a monitor for a week. It was unknown if patient had other vaccine in four weeks. It was also unknown if patient had covid prior to vaccination or covid tested post vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 52-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment information was provided.
Patient was admitted on 1/3/2022 for chief complaint of fatigue. Symptoms started 3 days prior to presentation. Patient was found to have Covid-19 pneumonia and was hypoxic. She was treated with Decadron and remdesivir but refused treatment at times during her hospitalization.  Her oxygen requirements were weaned during her hospitalization. She was evaluated for home O2 and did qualify as she desaturated to 87% with ambulation on room air.
The patient was given 2 doses of the Engerix-B at the same time.
patient has mixed adrenal insufficiency (prior tovaccines) and suffered from convulsions, neuropathy, migraines and more for most of her life. each dose gave her a rush of energy not felt since childhood within about 15 minutes, and in the days.; This spontaneous case was reported by a patient and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (patient has mixed adrenal insufficiency (prior tovaccines) and suffered from convulsions, neuropathy, migraines and more for most of her life. each dose gave her a rush of energy not felt since childhood within about 15 minutes, and in the days.) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Adrenal insufficiency since an unknown date. Previously administered products included for Product used for unknown indication: Pfizer (Dose Number: 1 Batch/Lot No: er8734) on 06-Apr-2021, Pfizer (Dose Number: 2 Batch/Lot No: er7533) on 27-Apr-2021 and Pfizer (Dose Number: 3 Batch/Lot No: fe3590) on 02-Nov-2021. Past adverse reactions to the above products included No adverse event with Pfizer, Pfizer and Pfizer. Concurrent medical conditions included Penicillin allergy, Convulsions, Neuropathy, Migraine, Chronic back pain and Food allergy. Concomitant products included TOPIRAMATE (TOPAMAX), CANNABINOIDS NOS and N-ACETYLCYSTEINE for an unknown indication.    On an unknown date, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (patient has mixed adrenal insufficiency (prior tovaccines) and suffered from convulsions, neuropathy, migraines and more for most of her life. each dose gave her a rush of energy not felt since childhood within about 15 minutes, and in the days.). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (patient has mixed adrenal insufficiency (prior tovaccines) and suffered from convulsions, neuropathy, migraines and more for most of her life. each dose gave her a rush of energy not felt since childhood within about 15 minutes, and in the days.) outcome was unknown.            This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.  The concomitant medication was reported as Angestrin.   Patient reported that she had mixed adrenal insufficiency (prior to vaccines) and suffered from convulsions, neuropathy, migraines, and more for most of her life and each dose gave her a rush of energy not felt since childhood' within about 15 minutes post vaccination, and her chronic back pain went away, food irritations, and other complications eased.  The treatment medication was not reported.
Pt. states after receiving J&J started feeling dizzy, vision turned white. She sit down to avoid falling, lasting about 5mins at a time. Attempted to get to her feet but shortly after standing repeated vision blurring and dizziness. Decided to just lay down for awhile. Spoke with Physician regarding symptoms with no explanation, still continuing to experience symptoms. Fear of passing out while driving.
Client received the Janssen Covid-19 vaccine. The dose was drawn into syringe on 05/04/2021 at 2:20 p.m. The dose should have been wasted at the end of the business day due to unknown stability after 6 hours after drawn up. The dose was not wasted and was given on 05/05/2021 at 1:30 p.m. During the 15 min waiting period the client did not present with any complications.
15 mnth old child given adult dose of H1N1 vaccine 0.5ml, child should have received pediatric dose of 0.25ml. Parent report no adverse reaction to vaccine.
The pt received 2nd dose of MMR on 8/23, 7 days later the pt developed rash on chest, arms, legs and face. The pt also complained of severe itching, raised papules that open and drain purulent drainage. The pt also complained that this also happened on the 1st dose.